Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2022-10-06 Interim / Quarterly Rep…
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
DEINOVE presents its financial results and the advancement of its programs for the first half of 2022
Interim / Quarterly Report Classification · 1% confidence The document provides a comprehensive overview of the company's financial performance for the first half of 2022, including detailed profit and loss accounts, cash flow data, and management commentary on operational progress. It is not merely an announcement of a report, but contains the actual financial statements and analysis for the interim period. Therefore, it is classified as an Interim/Quarterly Report. H1 2022
2022-10-06 English
DEINOVE présente des données sur DNV3837 au congrès ESCMID/ASM à Dublin
Regulatory Filings Classification · 1% confidence The document is a press release from DEINOVE announcing the presentation of preclinical and clinical data regarding their drug candidate DNV3837 at the ESCMID/ASM congress. It details scientific findings, patient case studies, and background information on *Clostridioides difficile* infections. This type of announcement, focusing on scientific updates, clinical trial progress, and strategic developments presented at conferences, is best classified as an Investor Presentation (IP) or a general press release detailing scientific progress. Since it is not a formal regulatory filing (like 10-K or IR), nor a transcript (CT), nor a formal earnings release (ER), and it functions as a detailed update for investors about their pipeline progress, 'Investor Presentation' (IP) is the most fitting category, even though it's presented as a press release summarizing presentation content. It is more detailed than a simple Earnings Release (ER) and focuses on scientific milestones rather than just financial results.
2022-10-05 French
DEINOVE to present data on DNV3837 at the ESCMID/ASM conference in Dublin
Regulatory Filings Classification · 1% confidence The document announces that DEINOVE will present data on its drug candidate DNV3837 at a scientific conference (ESCMID/ASM). It details preclinical results, a case study excerpt, and provides background information on the drug and the disease (CDI). This type of communication, focusing on scientific findings, clinical trial updates, and presentation schedules, is characteristic of an Investor Presentation (IP) or a general scientific/investor update, rather than a formal regulatory filing (like 10-K or IR) or a mandatory earnings release (ER). Since it is a detailed presentation of scientific and clinical progress aimed at investors and the scientific community, Investor Presentation (IP) is the most appropriate classification. It is not a short announcement of a report release (RPA/RNS) because it contains substantial content detailing the findings themselves.
2022-10-05 English
Mise en place d'un avenant au contrat d’OC conclu le 10 septembre 2021
Capital/Financing Update Classification · 1% confidence The document announces an amendment ("Avenant") to an existing convertible bond contract ("Contrat d'OC") dated September 10, 2021, involving the issuance of new tranches of convertible bonds (OC) and changes to the conversion discount and shareholder holding condition. This action directly relates to the company's financing activities and capital structure changes, specifically raising capital through debt instruments convertible into equity. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific financing event.
2022-08-03 French
DEINOVE - Adoption des résolutions de son Assemblée Générale Extraordinaire du 5 juillet 2022
AGM Information Classification · 1% confidence The document title explicitly states "DEINOVE - Adoption des résolutions de son Assemblée Générale Extraordinaire du 5 juillet 2022" (Adoption of the resolutions of its Extraordinary General Meeting of July 5, 2022). The content details the voting results, quorum achievement, and the adoption of resolutions from an Extraordinary General Meeting (EGM). This directly corresponds to the definition of AGM Information (AGM-R), which covers presentations and materials shared during General Meetings, including the results of votes taken.
2022-07-07 French
DEINOVE- Troisième convocation à une Assemblée générale extraordinaire le 5 juillet 2022
Proxy Solicitation & Information Statement Classification · 1% confidence The document explicitly discusses the 'Troisième convocation à une Assemblée générale extraordinaire' (Third call for an Extraordinary General Meeting) scheduled for July 5, 2022, because the quorum was not met at the previous meeting. It details the agenda, the appointment of a 'mandataire ad hoc' to ensure quorum, and provides instructions and forms for shareholders to vote by correspondence or proxy. This content is directly related to the preparation, solicitation, and scheduling of a shareholder meeting, which falls under the definition of Proxy Solicitation & Information Statement (PSI). While it relates to an AGM, the primary focus is the procedural announcement and solicitation of votes for the rescheduled meeting, making PSI more precise than AGM-R (which is usually the presentation materials themselves).
2022-06-22 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.